Page 2 - Complete Response News Today

- SLS009 Demonstrated Promising Efficacy in Phase 1 Study with 36.4% Clinical Response in r/r Peripheral T-cell Lymphomas ; ORR in r/r PTCL Patients with Standard of Care is 25.8% - - One Patient...

U.S. stocks traded higher midway through trading, with the Dow Jones index gaining around 50 points on Monday. The Dow traded up 0.14% to 37,356.29 while the NASDAQ rose 0.25% to 14,851.19. The S&P 500 also rose, gaining, 0.37% to 4,736.45.

Shares of Lantheus Holdings, Inc. (NASDAQ: LNTH) fell sharply during Monday’s session after the company and POINT Biopharma announced topline results from the pivotal phase 3 SPLASH study in metastatic castration-resistant prostate cancer.

U.S. stocks traded mostly higher toward the end of trading, with the Nasdaq Composite gaining over 100 points on Monday. The Dow traded up 0.01% to 37,307.40 while the NASDAQ rose 0.71% to 14,919.07. The S&P 500 also rose, gaining, 0.54% to 4,744.58.

Curis, Inc. announced initial combination study data from its Take Aim Lymphoma trial including 5 primary CNS lymphoma patients. As of October 12th, the Take Aim Lymphoma trial has enrolled and...

/PRNewswire/ -- Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has granted TAR-200 Breakthrough Therapy Designation (BTD)...

30.11.2023 - Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today ... Seite 1

Combined Analysis That Includes First Reported Data from Multicohort Phase 2 EBVision Trial Consistent with Previous Single-Center Experience Pooled Analysis Shows 77.8% Objective Response Rate in...

27.11.2023 - Resubmission of the ONS-5010 BLA on track for the end of calendar year 2024, pending final agreement on a clinical trial protocol with the FDA and successful completion of the required additional clinical trialPlanned clinical trial expected to be a ... Seite 1

Español img_7351.jpg ROVI REPORTS OPERATING REVENUE GROWTH OF 3% FOR THE FIRST NINE MONTHS OF THE FIRST POST-PANDEMIC...